- Home
- FSHP vs OVID Comparison
FSHP vs OVID Comparison
Compare FSHP & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- OVID
- Stock Information
- Founded
- FSHP 2018
- OVID 2014
- Country
- FSHP United States
- OVID United States
- Employees
- FSHP N/A
- OVID N/A
- Industry
- FSHP
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- FSHP
- OVID Health Care
- Exchange
- FSHP NYSE
- OVID Nasdaq
- Market Cap
- FSHP 92.2M
- OVID 20.6M
- IPO Year
- FSHP 2024
- OVID 2017
- Fundamental
- Price
- FSHP N/A
- OVID $0.34
- Analyst Decision
- FSHP
- OVID Strong Buy
- Analyst Count
- FSHP 0
- OVID 4
- Target Price
- FSHP N/A
- OVID $3.13
- AVG Volume (30 Days)
- FSHP 758.0
- OVID 1.7M
- Earning Date
- FSHP 01-01-0001
- OVID 08-12-2025
- Dividend Yield
- FSHP N/A
- OVID N/A
- EPS Growth
- FSHP N/A
- OVID N/A
- EPS
- FSHP 0.21
- OVID N/A
- Revenue
- FSHP N/A
- OVID $548,000.00
- Revenue This Year
- FSHP N/A
- OVID N/A
- Revenue Next Year
- FSHP N/A
- OVID $5.32
- P/E Ratio
- FSHP $49.03
- OVID N/A
- Revenue Growth
- FSHP N/A
- OVID 15.61
- 52 Week Low
- FSHP $9.99
- OVID $0.24
- 52 Week High
- FSHP $10.48
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- OVID 56.76
- Support Level
- FSHP N/A
- OVID $0.30
- Resistance Level
- FSHP N/A
- OVID $0.33
- Average True Range (ATR)
- FSHP 0.00
- OVID 0.03
- MACD
- FSHP 0.00
- OVID 0.00
- Stochastic Oscillator
- FSHP 0.00
- OVID 85.13
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.